Potassium cation
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Potassium cation
- DrugBank Accession Number
- DB01345
- Background
Potassium is the major cation (positive ion) inside animal cells, while sodium is the major cation outside animal cells. The concentration differences of these charged particles causes a difference in electric potential between the inside and outside of cells, known as the membrane potential. The balance between potassium and sodium is maintained by ion pumps in the cell membrane. The cell membrane potential created by potassium and sodium ions allows the cell generate an action potential—a "spike" of electrical discharge. The ability of cells to produce electrical discharge is critical for body functions such as neurotransmission, muscle contraction, and heart function. Potassium is also an essential mineral needed to regulate water balance, blood pressure and levels of acidity.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
- Weight
- Average: 39.0983
Monoisotopic: 38.963706861 - Chemical Formula
- K
- Synonyms
- Potassium (ion)
- Potassium ion
- potassium(1+)
- potassium(1+) ion
- potassium(I) cation
Pharmacology
- Indication
Potassium is used to regulate hypokalemia as a primary condition or secondary to other medical conditions.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Therapies
- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Potassium is the major cation (positive ion) inside animal cells, while sodium is the major cation outside animal cells. The concentration differences of these charged particles causes a difference in electric potential between the inside and outside of cells, known as the membrane potential. The balance between potassium and sodium is maintained by ion pumps in the cell membrane. The cell membrane potential created by potassium and sodium ions allows the cell generate an action potential—a "spike" of electrical discharge. The ability of cells to produce electrical discharge is critical for body functions such as neurotransmission, muscle contraction, and heart function. Potassium is also an essential mineral needed to regulate water balance, blood pressure and levels of acidity.
Target Actions Organism USodium/potassium-transporting ATPase subunit alpha-1 Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Mostly urine but also skin and feces.
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Abacavir may decrease the excretion rate of Potassium cation which could result in a higher serum level. Acebutolol Potassium cation may increase the hyperkalemic activities of Acebutolol. Aceclofenac Potassium cation may increase the hyperkalemic activities of Aceclofenac. Acemetacin The therapeutic efficacy of Potassium cation can be decreased when used in combination with Acemetacin. Acetaminophen Acetaminophen may decrease the excretion rate of Potassium cation which could result in a higher serum level. - Food Interactions
- No interactions found.
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image AMINOMIX Potassium cation (30 mmol/l) + Acetic acid (4.5 g/1000ml) + Alanine (7 g/1000ml) + Arginine (6 g/1000ml) + Calcium chloride dihydrate (0.294 g/100ml) + Dextrose, unspecified form (120 g/100ml) + Glycine (5.5 g/1000ml) + Histidine (1.5 g/1000ml) + Hydrochloric acid (1.47 ml) + Isoleucine (2.5 g/1000ml) + Leucine (3.7 g/1000ml) + Lysine (3.3 g/1000ml) + Magnesium chloride hexahydrate (0.61 g/100ml) + Methionine (2.15 g/1000ml) + Phenylalanine (2.55 g/1000ml) + Potassium hydroxide (1.981 g/100ml) + Proline (5.6 g/1000ml) + Serine (3.25 g/1000ml) + Sodium cation (50 mmol/l) + Sodium chloride (1.169 g/100ml) + Sodium glycerophosphate hydrate (4.59 g/1000ml) + Taurine (0.5 g/1000ml) + Threonine (2.2 g/1000ml) + Tryptophan (1 g/1000ml) + Tyrosine (0.2 g/1000ml) + Valine (3.1 g/1000ml) + Zinc chloride (0.00545 g/100ml) Injection, solution Intravenous Fresenius Kabi Italia S.R.L. 2014-07-08 Not applicable Italy AMINOMIX Potassium cation (30 mmol/l) + Acetic acid (4.5 g/1000ml) + Alanine (7 g/1000ml) + Arginine (6 g/1000ml) + Calcium chloride dihydrate (0.294 g/100ml) + Dextrose, unspecified form (120 g/100ml) + Glycine (5.5 g/1000ml) + Histidine (1.5 g/1000ml) + Hydrochloric acid (1.47 ml) + Isoleucine (2.5 g/1000ml) + Leucine (3.7 g/1000ml) + Lysine (3.3 g/1000ml) + Magnesium chloride hexahydrate (0.61 g/100ml) + Methionine (2.15 g/1000ml) + Phenylalanine (2.55 g/1000ml) + Potassium hydroxide (1.981 g/100ml) + Proline (5.6 g/1000ml) + Serine (3.25 g/1000ml) + Sodium cation (50 mmol/l) + Sodium chloride (1.169 g/100ml) + Sodium glycerophosphate hydrate (4.59 g/1000ml) + Taurine (0.5 g/1000ml) + Threonine (2.2 g/1000ml) + Tryptophan (1 g/1000ml) + Tyrosine (0.2 g/1000ml) + Valine (3.1 g/1000ml) + Zinc chloride (0.00545 g/100ml) Injection, solution Intravenous Fresenius Kabi Italia S.R.L. 2014-07-08 Not applicable Italy AMINOMIX Potassium cation (30 mmol/l) + Acetic acid (4.5 g/1000ml) + Alanine (7 g/1000ml) + Arginine (6 g/1000ml) + Calcium chloride dihydrate (0.294 g/100ml) + Dextrose, unspecified form (200 g/100ml) + Glycine (5.5 g/1000ml) + Histidine (1.5 g/1000ml) + Hydrochloric acid (1.47 ml) + Isoleucine (2.5 g/1000ml) + Leucine (3.7 g/1000ml) + Lysine (3.3 g/1000ml) + Magnesium chloride hexahydrate (0.61 g/100ml) + Methionine (2.15 g/1000ml) + Phenylalanine (2.55 g/1000ml) + Potassium hydroxide (1.981 g/100ml) + Proline (5.6 g/1000ml) + Serine (3.25 g/1000ml) + Sodium cation (50 mmol/l) + Sodium chloride (1.169 g/100ml) + Sodium glycerophosphate hydrate (4.59 g/1000ml) + Taurine (0.5 g/1000ml) + Threonine (2.2 g/1000ml) + Tryptophan (1 g/1000ml) + Tyrosine (0.2 g/1000ml) + Valine (3.1 g/1000ml) + Zinc chloride (0.00545 g/100ml) Injection, solution Intravenous Fresenius Kabi Italia S.R.L. 2014-07-08 Not applicable Italy AMINOMIX Potassium cation (30 mmol/l) + Acetic acid (4.5 g/1000ml) + Alanine (7 g/1000ml) + Arginine (6 g/1000ml) + Calcium chloride dihydrate (0.294 g/100ml) + Dextrose, unspecified form (120 g/100ml) + Glycine (5.5 g/1000ml) + Histidine (1.5 g/1000ml) + Hydrochloric acid (1.47 ml) + Isoleucine (2.5 g/1000ml) + Leucine (3.7 g/1000ml) + Lysine (3.3 g/1000ml) + Magnesium chloride hexahydrate (0.61 g/100ml) + Methionine (2.15 g/1000ml) + Phenylalanine (2.55 g/1000ml) + Potassium hydroxide (1.981 g/100ml) + Proline (5.6 g/1000ml) + Serine (3.25 g/1000ml) + Sodium cation (50 mmol/l) + Sodium chloride (1.169 g/100ml) + Sodium glycerophosphate hydrate (4.59 g/1000ml) + Taurine (0.5 g/1000ml) + Threonine (2.2 g/1000ml) + Tryptophan (1 g/1000ml) + Tyrosine (0.2 g/1000ml) + Valine (3.1 g/1000ml) + Zinc chloride (0.00545 g/100ml) Injection, solution Intravenous Fresenius Kabi Italia S.R.L. 2014-07-08 Not applicable Italy AMINOMIX Potassium cation (30 mmol/l) + Acetic acid (4.5 g/1000ml) + Alanine (7 g/1000ml) + Arginine (6 g/1000ml) + Calcium chloride dihydrate (0.294 g/100ml) + Dextrose, unspecified form (120 g/100ml) + Glycine (5.5 g/1000ml) + Histidine (1.5 g/1000ml) + Hydrochloric acid (1.47 ml) + Isoleucine (2.5 g/1000ml) + Leucine (3.7 g/1000ml) + Lysine (3.3 g/1000ml) + Magnesium chloride hexahydrate (0.61 g/100ml) + Methionine (2.15 g/1000ml) + Phenylalanine (2.55 g/1000ml) + Potassium hydroxide (1.981 g/100ml) + Proline (5.6 g/1000ml) + Serine (3.25 g/1000ml) + Sodium cation (50 mmol/l) + Sodium chloride (1.169 g/100ml) + Sodium glycerophosphate hydrate (4.59 g/1000ml) + Taurine (0.5 g/1000ml) + Threonine (2.2 g/1000ml) + Tryptophan (1 g/1000ml) + Tyrosine (0.2 g/1000ml) + Valine (3.1 g/1000ml) + Zinc chloride (0.00545 g/100ml) Injection, solution Intravenous Fresenius Kabi Italia S.R.L. 2014-07-08 Not applicable Italy - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Rurina Potassium cation (0.25 g/1L) + Chloride ion (0.11 g/1L) + Sulfate ion (3.6 g/1L) Liquid Topical TELOM-X GENE Co., Ltd. 2017-07-01 Not applicable US Rurina Potassium cation (0.25 g/1L) + Chloride ion (0.11 g/1L) + Sulfate ion (3.6 g/1L) Liquid Topical Nano Bio Tech Co.,Ltd 2017-07-01 Not applicable US Telom-X-gene Potassium cation (0.25 g/1L) + Chloride ion (0.11 g/1L) + Sulfate ion (3.6 g/1L) Liquid Topical TELOM-X GENE Co., Ltd. 2017-07-01 Not applicable US
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 295O53K152
- CAS number
- 24203-36-9
- InChI Key
- NPYPAHLBTDXSSS-UHFFFAOYSA-N
- InChI
- InChI=1S/K/q+1
- IUPAC Name
- potassium(1+) ion
- SMILES
- [K+]
References
- Synthesis Reference
John B. Sardisco, "Production of potassium sulfate and hydrogen chloride." U.S. Patent US4045543, issued 1865.
US4045543- General References
- Not Available
- External Links
- PDB Entries
- 1a3w / 1a3x / 1a49 / 1a5a / 1a5b / 1a9x / 1ad1 / 1ad4 / 1akd / 1aop … show 4292 more
- FDA label
- Download (632 KB)
- MSDS
- Download (139 KB)
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- American Regent
- Hospira Inc.
- Luitpold Pharmaceuticals Inc.
- Dosage Forms
Form Route Strength Injection, solution Intravenous Solution Intravenous Liquid Topical - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US6946149 No 2005-09-20 2023-03-07 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 1067 °C (potassium sulfate) MSDS boiling point (°C) 1689 °C (potassium sulfate) MSDS water solubility 110 g/l (20°C) (potassium sulfate) MSDS - Predicted Properties
Property Value Source logP 0.2 Chemaxon pKa (Strongest Acidic) 3.09 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 0 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 0 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 0 m3·mol-1 Chemaxon Polarizability 1.78 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 107.2122 predictedDeepCCS 1.0 (2019) [M+H]+ 108.93591 predictedDeepCCS 1.0 (2019) [M+Na]+ 115.6797 predictedDeepCCS 1.0 (2019)
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium ions, providing the energy for active transport of various nutrients (PubMed:29499166, PubMed:30388404). Could also be part of an osmosensory signaling pathway that senses body-fluid sodium levels and controls salt intake behavior as well as voluntary water intake to regulate sodium homeostasis (By similarity)
- Specific Function
- ATP binding
- Gene Name
- ATP1A1
- Uniprot ID
- P05023
- Uniprot Name
- Sodium/potassium-transporting ATPase subunit alpha-1
- Molecular Weight
- 112895.01 Da
References
- Silva E, Gomes P, Soares-da-Silva P: Overexpression of Na(+)/K (+)-ATPase parallels the increase in sodium transport and potassium recycling in an in vitro model of proximal tubule cellular ageing. J Membr Biol. 2006;212(3):163-75. Epub 2007 Feb 28. [Article]
- Li C, Geering K, Horisberger JD: The third sodium binding site of Na,K-ATPase is functionally linked to acidic pH-activated inward current. J Membr Biol. 2006;213(1):1-9. Epub 2007 Mar 8. [Article]
- Stanely Mainzen Prince P, Karthick M: Preventive effect of rutin on lipids, lipoproteins, and ATPases in normal and isoproterenol-induced myocardial infarction in rats. J Biochem Mol Toxicol. 2007;21(1):1-6. [Article]
- Simon WA, Herrmann M, Klein T, Shin JM, Huber R, Senn-Bilfinger J, Postius S: Soraprazan: setting new standards in inhibition of gastric acid secretion. J Pharmacol Exp Ther. 2007 Jun;321(3):866-74. Epub 2007 Mar 16. [Article]
- Iannello S, Milazzo P, Belfiore F: Animal and human tissue Na,K-ATPase in normal and insulin-resistant states: regulation, behaviour and interpretative hypothesis on NEFA effects. Obes Rev. 2007 May;8(3):231-51. [Article]
Drug created at June 30, 2007 18:13 / Updated at October 07, 2024 13:58